Real-world evaluation of TNF-inhibitor utilization in rheumatoid arthritis

References

• Silman AJ, Pearson JE. Epidemiology and genetics of rheumatoid arthritis. Arthritis Res 2002;4(Suppl 3):S265-72
   PubMedGoogle Scholar
• Scott DL, Wolfe F, Huizinga TW. Rheumatoid arthritis. Lancet 2010;376:1094-108
   PubMed Web of Science ®Google Scholar
• Cardarelli WJ. Implications for managed care and specialty pharmacy in rheumatoid arthritis. Am J Manag Care 2012;18:S315-24
   PubMedGoogle Scholar
• Kleinman NL, Cifaldi MA, Smeeding JE, et al. Annual incremental health benefit costs and absenteeism among employees with and without rheumatoid arthritis. J Occup Environ Med 2013;55:240-4
   PubMed Web of Science ®Google Scholar
• Singh JA, Furst DE, Bharat A, et al. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken) 2012;64:625-39
   PubMed Web of Science ®Google Scholar
• Smolen JS, Landewe R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis 2014;73:492-509
   PubMed Web of Science ®Google Scholar
• Li P, Blum MA, Von FJ, et al. Adherence, discontinuation, and switching of biologic therapies in medicaid enrollees with rheumatoid arthritis. Value Health 2010;13:805-12
   PubMed Web of Science ®Google Scholar
• Bonafede M, Fox KM, Watson C, et al. Treatment patterns in the first year after initiating tumor necrosis factor blockers in real-world settings. Adv Ther 2012;29:664-74
   PubMed Web of Science ®Google Scholar
• Yeaw J, Watson C, Fox KM, et al. Treatment patterns following discontinuation of adalimumab, etanercept, and infliximab in a US managed care sample. Adv Ther 2014;31:410-25
   PubMed Web of Science ®Google Scholar
• Harrold LR, Reed GW, Kremer JM, et al. The comparative effectiveness of abatacept versus anti-tumour necrosis factor switching for rheumatoid arthritis patients previously treated with an anti-tumour necrosis factor. Ann Rheum Dis 2015;74:430-6
   PubMed Web of Science ®Google Scholar
• Rendas-Baum R, Wallenstein GV, Koncz T, et al. Evaluating the efficacy of sequential biologic therapies for rheumatoid arthritis patients with an inadequate response to tumor necrosis factor-alpha inhibitors. Arthritis Res Ther 2011;13:R25
   PubMed Web of Science ®Google Scholar
• Kim HL, Lee MY, Park SY, et al. Comparative effectiveness of cycling of tumor necrosis factor-alpha (TNF-alpha) inhibitors versus switching to non-TNF biologics in rheumatoid arthritis patients with inadequate response to TNF-alpha inhibitor using a Bayesian approach. Arch Pharm Res 2014;37:662-70
   PubMed Web of Science ®Google Scholar
• Bartelds GM, Wijbrandts CA, Nurmohamed MT, et al. Anti-infliximab and anti-adalimumab antibodies in relation to response to adalimumab in infliximab switchers and anti-tumour necrosis factor naive patients: a cohort study. Ann Rheum Dis 2010;69:817-21
   PubMed Web of Science ®Google Scholar
• Krieckaert CL, Nurmohamed MT, Wolbink GJ. Methotrexate reduces immunogenicity in adalimumab treated rheumatoid arthritis patients in a dose dependent manner. Ann Rheum Dis 2012;71:1914-15
   PubMed Web of Science ®Google Scholar
• Burmester GR, Kivitz AJ, Kupper H, et al. Efficacy and safety of ascending methotrexate dose in combination with adalimumab: the randomised CONCERTO trial. Ann Rheum Dis 2015;74:1037-44
   PubMed Web of Science ®Google Scholar
• Maini RN, Breedveld FC, Kalden JR, et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 1998;41:1552-63
   PubMed Web of Science ®Google Scholar
• Soliman MM, Ashcroft DM, Watson KD, et al. Impact of concomitant use of DMARDs on the persistence with anti-TNF therapies in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis 2011;70:583-9
   PubMed Web of Science ®Google Scholar
• Meissner B, Trivedi D, You M, et al. Switching of biologic disease modifying anti-rheumatic drugs in patients with rheumatoid arthritis in a real world setting. J Med Econ 2014;17:259-65
   PubMedGoogle Scholar
• Curkendall S, Patel V, Gleeson M, et al. Compliance with biologic therapies for rheumatoid arthritis: do patient out-of-pocket payments matter? Arthritis Rheum 2008;59:1519-26
   PubMed Web of Science ®Google Scholar
• Borah BJ, Huang X, Zarotsky V, et al. Trends in RA patients' adherence to subcutaneous anti-TNF therapies and costs. Curr Med Res Opin 2009;25:1365-77
   PubMed Web of Science ®Google Scholar
• Blume SW, Fox KM, Joseph G, et al. Tumor necrosis factor-blocker dose escalation in rheumatoid arthritis patients in a pharmacy benefit management setting. Adv Ther 2013;30:517-27
   PubMed Web of Science ®Google Scholar
• Schabert VF, Watson C, Joseph GJ, et al. Costs of tumor necrosis factor blockers per treated patient using real-world drug data in a managed care population. J Manag Care Pharm 2013;19:621-30
   PubMed Web of Science ®Google Scholar
• Bonafede M, Joseph GJ, Shah N, et al. Cost of tumor necrosis factor blockers per patient with rheumatoid arthritis in a multistate Medicaid population. Clinicoecon Outcomes Res 2014;6:381-8
   PubMedGoogle Scholar
• Curtis JR, Schabert VF, Yeaw J, et al. Use of a validated algorithm to estimate the annual cost of effective biologic treatment for rheumatoid arthritis. J Med Econ 2014;17:555-66
   PubMedGoogle Scholar
• Ogale S, Hitraya E, Henk HJ. Patterns of biologic agent utilization among patients with rheumatoid arthritis: a retrospective cohort study. BMC Musculoskelet Disord 2011;12:204
   PubMed Web of Science ®Google Scholar
• Mueller CS, Wade S, Song X, et al. Calculation of annual biologic treatment costs in rheumatoid arthritis: a comparison of methods and relationship to adherence. J Manag Care Spec Pharm 2012;18:164
   Google Scholar
• Fisher A, Bassett K, Wright JM, et al. Comparative persistence of the TNF antagonists in rheumatoid arthritis–a population-based cohort study. PLoS One 2014;9:e105193
   PubMed Web of Science ®Google Scholar
• Fisher A, Bassett K, Wright JM, et al. Prescriber preference for a particular tumour necrosis factor antagonist drug and treatment discontinuation: population-based cohort. BMJ Open 2014;4:e005532
   PubMedGoogle Scholar
• Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40:373-83
   PubMedGoogle Scholar
• Ting G, Schneeweiss S, Scranton R, et al. Development of a health care utilisation data-based index for rheumatoid arthritis severity: a preliminary study. Arthritis Res Ther 2008;10:R95
   PubMed Web of Science ®Google Scholar
• Agarwal SK, Glass RJ, Shadick NA, et al. Predictors of discontinuation of tumor necrosis factor inhibitors in patients with rheumatoid arthritis. J Rheumatol 2008;35:1737-44
   PubMed Web of Science ®Google Scholar
• Yazici Y, Krasnokutsky S, Barnes JP, et al. Changing patterns of tumor necrosis factor inhibitor use in 9074 patients with rheumatoid arthritis. J Rheumatol 2009;36:907-13
   PubMed Web of Science ®Google Scholar
• Wu E, Chen L, Birnbaum H, et al. Retrospective claims data analysis of dosage adjustment patterns of TNF antagonists among patients with rheumatoid arthritis. Curr Med Res Opin 2008;24:2229-40
   PubMed Web of Science ®Google Scholar
• Gilbert TD, Jr, Smith D, Ollendorf DA. Patterns of use, dosing, and economic impact of biologic agent use in patients with rheumatoid arthritis: a retrospective cohort study. BMC Musculoskelet Disord 2004;5:36
   PubMed Web of Science ®Google Scholar
• Ollendorf DA, Massarotti E, Birbara C, et al. Frequency, predictors, and economic impact of upward dose adjustment of infliximab in managed care patients with rheumatoid arthritis. J Manag Care Pharm 2005;11:383-93
   PubMedGoogle Scholar
• Nair KV, Tang B, Van Den BJ, et al. Categorization of infliximab dose changes and healthcare utilization and expenditures for patients with rheumatoid arthritis in commercially insured and Medicare-eligible populations. Curr Med Res Opin 2009;25:303-14
   PubMed Web of Science ®Google Scholar
• Gu NY, Huang X, Fox KM, et al. Claims data analysis of dosing and cost of TNF antagonist. Am J Pharm Benefits 2010;2:351-9
   Google Scholar
• Harrison DJ, Huang X, Globe D. Dosing patterns and costs of tumor necrosis factor inhibitor use for rheumatoid arthritis. Am J Health Syst Pharm 2010;67:1281-7
   PubMed Web of Science ®Google Scholar
• Moots RJ, Haraoui B, Matucci-Cerinic M, et al. Differences in biologic dose-escalation, non-biologic and steroid intensification among three anti-TNF agents: evidence from clinical practice. Clin Exp Rheumatol 2011;29:26-34
   PubMed Web of Science ®Google Scholar
• Moots RJ, Mays R, Stephens J, et al. Burden of dose escalation with tumour necrosis factor inhibitors in rheumatoid arthritis: a systematic review of frequency and costs. Clin Exp Rheumatol 2015;33:737-45
   PubMed Web of Science ®Google Scholar
• Rosenblatt L, Lobo F, Cockrum P, et al. Biologic switching rates among patients with rheumatoid arthritis. Arthritis Rheum 2013;65:S998
   Google Scholar
• Karlsson JA, Kristensen LE, Kapetanovic MC, et al. Treatment response to a second or third TNF-inhibitor in RA: results from the South Swedish Arthritis Treatment Group Register. Rheumatology (Oxford) 2008;47:507-13
   PubMed Web of Science ®Google Scholar
• Hyrich KL, Lunt M, Watson KD, et al. Outcomes after switching from one anti-tumor necrosis factor alpha agent to a second anti-tumor necrosis factor alpha agent in patients with rheumatoid arthritis: results from a large UK national cohort study. Arthritis Rheum 2007;56:13-20
   PubMed Web of Science ®Google Scholar
• Finckh A, Ciurea A, Brulhart L, et al. Which subgroup of rheumatoid arthritis patients benefits from switching to rituximab versus alternative anti-TNF agents after previous failure to anti-TNF agent? Ann Rheum Dis 2010;69:387-93
   PubMed Web of Science ®Google Scholar
• van Vollenhoven RF. Switching between anti-tumour necrosis factors: trying to get a handle on a complex issue. Ann Rheum Dis 2007;66:849-51
   PubMed Web of Science ®Google Scholar
• Emery P, Sebba A, Huizinga TW. Biologic and oral disease-modifying antirheumatic drug monotherapy in rheumatoid arthritis. Ann Rheum Dis 2013;72:1897-904
   PubMed Web of Science ®Google Scholar
• Scott DL, Ibrahim F, Farewell V, et al. Tumour necrosis factor inhibitors versus combination intensive therapy with conventional disease modifying anti-rheumatic drugs in established rheumatoid arthritis: TACIT non-inferiority randomised controlled trial. BMJ 2015;350:h1046
   PubMedGoogle Scholar
• Jansen JP, Buckley F, Dejonckheere F, et al. Comparative efficacy of biologics as monotherapy and in combination with methotrexate on patient reported outcomes (PROs) in rheumatoid arthritis patients with an inadequate response to conventional DMARDs - a systematic review and network meta-analysis. Health Qual Life Outcomes 2014;12:102
   PubMed Web of Science ®Google Scholar
• Finckh A, Dehler S, Gabay C. The effectiveness of leflunomide as a co-therapy of tumour necrosis factor inhibitors in rheumatoid arthritis: a population-based study. Ann Rheum Dis 2009;68:33-9
   PubMed Web of Science ®Google Scholar
• Heiberg MS, Koldingsnes W, Mikkelsen K, et al. The comparative one-year performance of anti-tumor necrosis factor alpha drugs in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: results from a longitudinal, observational, multicenter study. Arthritis Rheum 2008;59:234-40
   PubMed Web of Science ®Google Scholar
• Kristensen LE, Saxne T, Nilsson JA, et al. Impact of concomitant DMARD therapy on adherence to treatment with etanercept and infliximab in rheumatoid arthritis. Results from a six-year observational study in southern Sweden. Arthritis Res Ther 2006;8:R174
   PubMed Web of Science ®Google Scholar
• Ostergaard M, Unkerskov J, Linde L, et al. Low remission rates but long drug survival in rheumatoid arthritis patients treated with infliximab or etanercept: results from the nationwide Danish DANBIO database. Scand J Rheumatol 2007;36:151-4
   PubMed Web of Science ®Google Scholar
• Tang B, Rahman M, Waters HC, et al. Treatment persistence with adalimumab, etanercept, or infliximab in combination with methotrexate and the effects on health care costs in patients with rheumatoid arthritis. Clin Ther 2008;30:1375-84
   PubMed Web of Science ®Google Scholar
• Zink A, Listing J, Kary S, et al. Treatment continuation in patients receiving biological agents or conventional DMARD therapy. Ann Rheum Dis 2005;64:1274-9
   PubMed Web of Science ®Google Scholar
• Lopez-Garcia R, Leon L, Loza E, et al. Adherence to biologic therapies and associated factors in rheumatoid arthritis, spondyloarthritis and psoriatic arthritis: a systematic literature review. Clin Exp Rheumatol. 2015;33:559–69
   Google Scholar
• US Food and Drug Administration. XELJANZ® (tofacitinib) tablets for oral administration, highlights of prescribing information. 2012. http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203214s000lbl.pdf. Accessed May 1, 2013
   Google Scholar
• US Food and Drug Administration. Orencia® (abatacept): highlights of prescribing information. 2011. http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/125118s0138lbl.pdf. Accessed August 19, 2015
   Google Scholar
• US Food and Drug Administration. ACTEMRA® (tocilizumab): highlights of prescribing information. 2013. http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/125276s092lbl.pdf. Accessed August 31, 2015
   Google Scholar